Argos Therapeutics (ARGS) Earns Daily News Impact Rating of 0.56
Media stories about Argos Therapeutics (NASDAQ:ARGS) have trended very positive this week, AlphaOne reports. AlphaOne, a service of Accern, identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Argos Therapeutics earned a media sentiment score of 0.56 on AlphaOne’s scale. AlphaOne also gave news coverage about the biopharmaceutical company an impact score of 100 out of 100, meaning that recent news coverage is extremely likely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have impacted AlphaOne Sentiment Analysis’s scoring:
- Argos Therapeutics, Inc. (ARGS) is at $0.39 per share and GenMark Diagnostics, Inc. (GNMK) is listed at $12.02 – Stocks Gallery (stocksgallery.com)
- Argos Therapeutics (ARGS) Announces $6M Secured Convertible Note Financing – StreetInsider.com (streetinsider.com)
- Argos Therapeutics : Announces $6,000,000 Secured Convertible Note Financing (4-traders.com)
- Technical Reports on Biotech Equities — Amgen, Pulmatrix, Argos Therapeutics, and Bioverativ – PR Newswire (press release) (prnewswire.com)
Several research analysts have recently weighed in on the stock. Needham & Company LLC cut shares of Argos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 22nd. FBR & Co cut shares of Argos Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $13.00 to $2.00 in a report on Wednesday, February 22nd. JMP Securities cut shares of Argos Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 22nd. Stifel Nicolaus cut shares of Argos Therapeutics from a “buy” rating to a “hold” rating and set a $1.40 price target for the company. in a report on Wednesday, February 22nd. Finally, Zacks Investment Research cut shares of Argos Therapeutics from a “buy” rating to a “sell” rating in a report on Monday, May 15th. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the stock. Argos Therapeutics presently has an average rating of “Hold” and a consensus target price of $4.78.
Shares of Argos Therapeutics (ARGS) traded down 0.6113% during mid-day trading on Friday, hitting $0.3902. 233,864 shares of the stock were exchanged. The stock’s market capitalization is $16.14 million. Argos Therapeutics has a 12-month low of $0.31 and a 12-month high of $7.08. The stock’s 50 day moving average price is $0.43 and its 200-day moving average price is $2.37.
About Argos Therapeutics
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.